Sonoma Pharmaceuticals (NASDAQ:SNOA) Announces Earnings Results

Posted by Brenda Bartman on Aug 7th, 2026

Sonoma Pharmaceuticals (NASDAQ:SNOA – Get Free Report) announced its quarterly earnings data on Thursday. The company reported $0.02 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.32, Zacks reports. Sonoma Pharmaceuticals had a negative return on equity of 43.95% and a negative net margin of 16.26%.The company had revenue of $6.41 million for the quarter, compared to the consensus estimate of $4.99 million.

Sonoma Pharmaceuticals Trading Up 13.2%

SNOA stock traded up $0.17 during trading on Friday, reaching $1.42. 755,724 shares of the stock were exchanged, compared to its average volume of 130,729. The firm’s 50 day moving average is $1.17 and its 200 day moving average is $1.89. Sonoma Pharmaceuticals has a twelve month low of $0.85 and a twelve month high of $6.92. The firm has a market cap of $6.78 million, a P/E ratio of -0.75 and a beta of 1.28.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Sonoma Pharmaceuticals in a research note on Friday, July 24th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock has a consensus rating of “Sell”.

Read Our Latest Research Report on Sonoma Pharmaceuticals

Institutional Investors Weigh In On Sonoma Pharmaceuticals

A hedge fund recently raised its stake in Sonoma Pharmaceuticals stock. DRW Securities LLC lifted its position in shares of Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA – Free Report) by 257.2% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 60,977 shares of the company’s stock after purchasing an additional 43,907 shares during the quarter. DRW Securities LLC owned 3.59% of Sonoma Pharmaceuticals worth $222,000 at the end of the most recent reporting period. 1.95% of the stock is owned by institutional investors.

About Sonoma Pharmaceuticals

(Get Free Report)

Sonoma Pharmaceuticals, Inc is a specialty dermatology company focused on developing and commercializing topical prescription and over-the-counter products for inflammatory and infectious skin conditions. Publicly traded on Nasdaq under the symbol SNOA, the company concentrates its efforts on areas such as acne, rosacea, dermatitis and wound care, aiming to provide physicians and patients with innovative treatment options.

At the heart of Sonoma’s technology platform lies its proprietary Triphasic drug delivery system, which enables the timed release of active ingredients through three distinct gel phases.